Publication Name	World Journal of Gastroenterology
Manuscript ID	38931
Country	South Korea

Received	2018-03-25 06:21
Peer-Review Started	2018-03-25 11:59
To Make the First Decision	2018-04-11 06:47
Return for Revision	2018-04-18 08:56
Revised	2018-04-23 05:46
Second Decision	2018-04-25 10:50
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2018-04-26 02:15
Articles in Press	2018-04-26 02:15
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2018-05-04 10:04
Publish the Manuscript Online	2018-05-06 13:12

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Anti-integrin therapy for inflammatory bowel disease
Manuscript Source	Invited Manuscript
All Author List	Sung Chul Park and Yoon Tae Jeen
ORCID	Author(s) ORCID Number Sung Chul Park http://orcid.org/0000-0003-3215-6838 Yoon Tae Jeen http://orcid.org/0000-0003-0220-3816
Funding Agency and Grant Number
Corresponding Author	Yoon Tae Jeen, MD, PhD, Professor, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, 73, Inchon-ro, Seongbuk-gu, Seoul 02841, South Korea. ytjeen@korea.ac.kr
Key Words	Integrin; Ulcerative colitis; Crohn’s disease; Natalizumab; Abrilumab; Etrolizumab; PF-00547659; Inflammatory bowel disease; AJM300; Vedolizumab
Core Tip	Anti-integrin therapies have attracted attention as new therapeutic agents in inflammatory bowel dis­ease. They inhibit the extravasation of leukocytes by blocking the interaction between integrins on immune cells and endothelial cell adhesion molecules. The use of the first developed anti-integrin agent, natalizumab is now limited due to the risk of progressive multifocal leukoencephalopathy. However, vedolizumab which acts selectively on the gut has shown few adverse events and is currently used in clinical practice. Newer anti-integrin drugs that act on different integrins-related targets, such as AJM300, abrilumab, etrolizumab, and PF-00547659 have also been developed and are in clinical trials.
Publish Date	2018-05-06 13:12
Citation	Park SC, Jeen YT. Anti-integrin therapy for inflammatory bowel disease. World J Gastroenterol 2018; 24(17): 1868-1880
URL	http://www.wjgnet.com/1007-9327/full/v24/i17/1868.htm
DOI	http://dx.doi.org/10.3748/wjg.v24.i17.1868

Full Article (PDF)	WJG-24-1868.pdf
Manuscript File	38931-Review.docx
Answering Reviewers	38931-Answering reviewers.pdf
Audio Core Tip	38931-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	38931-Conflict-of-interest statement.pdf
Copyright License Agreement	38931-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	38931-Language certificate.pdf
Peer-review Report	38931-Peer-review(s).pdf
Scientific Misconduct Check	38931-Scientific misconduct check.pdf
Scientific Editor Work List	38931-Scientific editor work list.pdf